A trial of CD19-targeting chimeric antigen receptor (CAR)-T cell therapy for relapsed mantle cell lymphoma has proved promising, a conference has heard.
The ZUMA-2 trial has found improved outcomes for patients on the therapy, after their disease had relapsed following treatments including Bruton’s tyrosine kinase inhibitor agents, researchers reported.
The trial was led by Dr Michael Wang and his team at The University of Texas MD Anderson Cancer Center, USA. They say that after a year, most patients who had previously relapsed achieved complete response. More than 80% of the patients had had stage IV disease at the beginning of the study.
The overall response rate to CAR‑T cell therapy was 93%, and 67% achieved a complete response. Now after two years, 43% of the first group of 28 patients treated are still in remission.
The findings suggest most patients with mantle cell lymphoma who are resistant to prior therapies may benefit from treatment with the new CD19-targeting CAR‑T cell therapy.
The results were presented at the American Society of Hematology annual meeting in Orlando, Florida, USA.
Dr Wang stated: “Outcomes for patients whose disease progresses following initial treatments is poor. Our study demonstrated significant and durable clinical benefit for patients with relapsed or refractory mantle cell lymphoma for which there are no curative treatment options.”
He added: “ZUMA-2 is the first multi-centre, Phase II study of CAR T-cell therapy for relapsed/refractory mantle cell lymphoma and these interim efficacy and safety results are encouraging.
“Although this study continues, our reported results, including a manageable safety profile, point to this therapy as an effective and viable option for patients with relapsed or refractory mantle cell lymphoma.”
Source: ASH Abstract 754: KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study